Table 2. Detection results of HPV DNA, mRNA, EBNA-3C, the 30 bp deletion LMP-1 variant, and EBER in different types of head and neck cancer.

Site of origin	HPV DNA, n (%)*	HPV mRNA, n (%)#	EBNA-3C, n (%)*	del-LMP-1, n (%)*	EBER, n (%)*	HPV DNA and EBER, n (%)*
Nasopharynx n = 20	6 (30.0%)	1 (16.7%)	19 (95%)	17 (85.0%)	12 (60.0%)	2 (10.0%)
Oropharynx n = 74	34 (45.9%)	20 (60.6%)	59 (79.7%)	47 (63.5%)	1 (1.4%)	0
Hypopharynx n = 50	8 (16.0%)	0	32 (64.0%)	27 (54.0%)	0	0
Larynx n = 28	4 (14.3%)	1 (33.3%)	14 (50.0%)	10 (35.7%	0	0
Oral cavity n = 37	11 (29.7%)	1 (9.1%)	22 (59.5%)	22 (59.5%)	0	0

HPV, human papillomavirus; EBNA, Epstein-Barr nuclear antigen; LMP-1, latent membrane protein-1; EBER, Epstein-Barr virus encoded RNA.

* Positive rate of the variables in different subsites of head and neck cancer.

^#Positive rate of HPV mRNA in HPV DNA-positive patients; 3 cases with HPV DNA-positive derived from oropharynx, hypopharynx, and larynx were not sufficient to be examined for RNA extraction and E6/E7 mRNA expression.